RGD peptides are popular drug delivery tools in treating integrin V3-expressing malignant tumors and tumor vasculature cells. We investigated the specific delivery and pharmacological potential of enantiomeric mitochondria-disruptive peptides (RLYLRIGRR-NH 2 , RLRLRIGRR-NH 2 , ALYLAIRRR-NH 2 , and RLLLRIGRR-NH 2 ) after conjugation with an integrin V3-homing peptide, cyclic pentameric RGD peptide. The cyclic RGD-conjugated mitochondria-disruptive peptides exhibited specific internalization, apoptosis induction, and cytotoxicity against integrin V3-high-expressing human umbilical vein endothelial cells. Our findings indicate that these novel peptide complexes might prove good anti-angiogenesis reagents.
Mitochondria are organelles that play important roles in, for example, energy metabolism, reactive oxygen species production, intracellular calcium control, and apoptosis regulation 1) in all eukaryote cells. Hence, mitochondria have drawn attention as a promising target for drug discovery in combination with a drug delivery system (DDS). 2) In particular, antimicrobial peptides (AMPs) are regarded as suitable materials for mitochondria-targeting strategies. AMPs are short cationic peptides that disrupt negatively charged bacterial membranes by charge interactions. 3, 4) In a recent study, an AMP-like D-peptide (KLAKLAKKLAKLAK-OH) was found to disrupt mitochondria and to exhibit significant cytotoxicity when it was delivered artificially into the cytoplasm. 5) These effects are considered to be attributable to negative charges in the mitochondrial outer membrane. Mitochondria are posited to be derived from aerobic bacteria in the endosymbiotic theory, 6) and have a negatively charged outer membrane similar to the bacterial membrane. 7) Therefore, cationic AMP-like peptides are thought to interact with and to disrupt the negatively charged mitochondrial membrane by charge interactions.
Previously, we reported the synthesis and functions of four AMP-like short peptides termed D9mer peptides, DA (RLYLRIGRR-NH 2 ), DB (RLRLRIGRR-NH 2 ), DC (ALYLAIRRR-NH 2 ), and DD (RLLLRIGRR-NH 2 ). [8] [9] [10] [11] Their sequences were synthesized using D-amino acids and were amidated in the C-terminus. All these D9mer peptides were designed and synthesized on the basis of insect AMPs, defensins, using D-amino acids and the Cterminal amidated structure. 12, 13) They showed cationic and amphipathic structures 14) and have been reported to have multiple functions, including antimicrobial, antiprotozoan, and antitumor activities, on the basis of disruption of negatively charged target membranes. [8] [9] [10] Furthermore, our latest study revealed that they can disrupt the mitochondrial membrane by the mechanism described above, i.e., they disrupt negatively charged mitochondrial membranes by charge interactions.
11)
These observations suggest that D9mer peptides are good candidates for mitochondria-targeting strategies in combination with a DDS. Hence a new peptide named DC2 (ALYLAIRRRRRRRR-NH 2 ) was designed and synthesized by connecting DC to D-octa-arginine (RRRRRRRR-NH 2 ) via sharing of arginine residues in the C-terminus to target mitochondria. Octa-arginine is a major cell-penetrating peptide (CPP), and was reported to show effective uptake into cells via interactions between the cationic octa-arginine and anionic proteoglycans on the membrane surface.
15) D-Octa-arginine was also found to have effective membrane permeability similar to L-octa-arginine, 16) because arginine residues take on the same net charges regardless of the presence of the L-or D-amino acid. In fact, DC2 penetrated the cell membrane, caused mitochondrial disruption, and showed higher cytotoxicity against various cell lines than DC, 14) but DC2 showed no cytoselectivity, and killed not only tumor cell lines but also a normal fibroblastic cell line (MRC-5). These findings indicate that octa-arginine is not a suitable DDS tool for D9mer peptides due to its non-specific cell-penetrating properties, although mitochondria targeting is an effective strategy for D9mer peptides.
In this study, we tried to control the cytoselectivity of mitochondria-disruptive D9mer peptides using a target cell-specific DDS. We focused on a DDS peptide, cyclic Arg-Gly-Asp (cRGD) peptide, as a target cell-specific transporter for D9mer peptides. The cRGD peptide is y To whom correspondence should be addressed. Fax: +81-29-838-6028; E-mail: bishiba@nias.affrc.go.jp Abbreviations: AMP, antimicrobial peptide; CPP, cell-penetrating peptide; DDS, drug delivery system; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; HUVEC, human umbilical vein endothelial cell; LDH, lactate dehydrogenase; TAMRA, tetramethyl rhodamine known to translocate into cells expressing an extracellular target molecule, integrin V3, by binding to it and inducing endocytosis in it. 17) Integrin V3 is an extracellular cell-adhesion protein complex that is significantly overexpressed on vascular cells during tumor angiogenesis, but is absent from the quiescent endothelium and normal tissues. 18) This indicates that it can be a specific target for antitumor angiogenesis drugs. Here we report the synthesis, cytoselectivity, and cytotoxicity of integrin V3-targeting mitochondriadisruptive peptides, cRGD-cys-D9mer peptides, against various cell lines.
Materials and Methods
Cell lines. Cos-1 African green monkey kidney cancer (Riken Cell Bank, RCB0143), HepG2 human liver cancer (RCB1886), and NIH-3T3 mouse fibroblastic (RCB2767) cell lines were cultured in DMEM (Invitrogen, Carlsbad, CA). The RERF-LC-AI human carcinoma (RCB0444) cell line was cultured in MEM (Invitrogen). Human umbilical vein endothelial cells (HUVECs) (Lonza, Basal, Switzerland) were cultured in EBM-2 (Lonza). All media contained 10% (v/v) fetal bovine serum (FBS).
Peptide synthesis, cyclization, and purification. D9mer peptides DA (RLYLRIGRR-NH 2 ), DB (RLRLRIGRR-NH 2 ), DC (ALYLAIRRR-NH 2 ), and DD (RLLLRIGRR-NH 2 ) and cys-D9mer peptides cys-DA, cys-DB, cys-DC, and cys-DD were synthesized by a 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthetic method on Rink-amide-MBHA resin (Merck Chemicals, Darmstadt, Germany) using an APEX 396 automatic peptide synthesizer (Advanced ChemTech, Louisville, KT). Subsequently, the peptides were cleaved from the resin, and the side chains were deprotected using a mixture of trifluoroacetic acid/ m-cresol/thioanisole/ethane-1,2-dithiol (35:2:2:1, v/v) for 4 h at room temperature.
A side chain-protected linear RGD peptide, H-Asp(OtBu)-D-PheCys(Trt)-Arg(Pbf)-Gly-OH, was synthesized on HMB resin (Merck) by the method described above and cleaved from the dried resin using a mixture of dichloromethane/methanol/acetic acid (8:1:1, v/v) for 2 h at room temperature. The mixture was evaporated, and the lyophilized linear RGD peptide was dissolved in N,N-dimethylformamide (1 mg/ mL). Next, six equivalents of 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and six equivalents N,N-diisopropylethylamine (DIPEA) were added to the peptide solution. After 24 h, cyclization was complete. The solvent was evaporated, and the crude products were precipitated with deionized water. The cyclized RGD peptide was deprotected under the conditions described above.
The crude products were precipitated with cold diethyl ether and purified using an HP1100 HPLC system (Hitachi, Tokyo) with a reverse-phase PEGASIL ODS column (Senshu-Pak, Tokyo). The purified D9mer peptides, cys-D9mer peptides, and cRGD peptide, cyclo(-Asp-D-Phe-Cys-Arg-Gly-), were characterized by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Autoflex III; Bruker Daltonics, Billerica, MA).
The lyophilized cRGD peptide was dissolved in 2-propanol/acetic acid (1:1, v/v) and added to 3 mM 2,2 0 -dithiodipyridine in the same solution to introduce an S-pyridyl (S-pyr) group to the thiol group of the cysteine residue in the cRGD peptide. The resulting cRGD(S-pyr) peptide, cyclo[-Asp-D-Phe-Cys(S-pyr)-Arg-Gly-], was purified using AKTA Explore (GE Healthcare, Little Chalfont, UK) and a Superdex Peptide column (GE Healthcare), lyophilized, and resolved in 0.5 M Tris(hydroxymethyl)aminomethane-HCl (pH 8.5). Two equivalents of cys-D9mer peptides in 5 mM HCl were added dropwise to this solution with gentle stirring. The combined peptides, cRGD-cys-D9mer peptides (cRGD-cys-DA, DB, DC, and DD), were obtained after 24 h at room temperature (Fig. 1) . The final compounds were purified using AKTA Explore and a Superdex Peptide column, and high-purity peptides (theoretical purity, >95%) were prepared.
Measurements of integrin V3 expression. The expression levels of integrin V3 in the various cell types (HUVECs, Cos-1 monkey kidney cancer cells, RERF-LC-AI human lung cancer cells, HepG2 human liver cancer cells, and NIH-3T3 mouse fibroblasts) were evaluated by flow cytometric analysis. Integrin V3 expressed on the membrane surface was stained with an anti-integrin V3 antibody conjugated with fluorescein isothiocyanate (FITC) (Bio Vision, Mountain View, CA) and detected by flow cytometry (Epics XL-MCL Flow Cytometry System; Beckman Coulter, Fullerton, CA). The cells were collected and washed twice with FACS medium (1 mM CaCl 2 , 0.5 mM MgCl 2 , 5% FBS, 0.5% bovine serum albumin, and 0.1% NaN 3 in phosphate-buffered saline) by centrifugation at 300 Â g for 5 min. Next, 100 mL of antibody solution (25 mg/mL) was added to the cells (2:0 Â 10 5 ). After 30 min of incubation on ice, the cells were washed twice with FACS medium, suspended in 1 mL of FACS medium, and analyzed by flow cytometry within 2 h. The mean fluorescence intensity (MFI) of more than 1 Â 10 4 cells was determined, and the integrin V3 expression level was quantified for each cell line.
Cytotoxicity assay. The various cell lines were seeded onto 96-well plates at a density of 8:0 Â 10 3 cells/well in 100 mL of medium containing various concentrations of peptides (12.5, 25, 50, 75, and 100 mM). The cells were incubated under 5% CO 2 for 24 h at 37 C, and then 10 mL of Cell Counting Kit-8 Reaction Solution (Dojindo, Kumamoto, Japan) was added to each well. After 4 h of incubation, the absorbance was measured at 450 nm using an automated plate reader (Appliskan; Thermo Fisher Scientific, Waltham, MA). Cell viability relative to the untreated cells was determined, and the cytotoxicities of peptides were evaluated.
Observation of internalization. The internalization of the cRGDcys-D9mer peptides into integrin V3-high-expressing and V3-low-expressing cell lines was observed. Tetramethyl rhodamine (TAMRA) (Invitrogen) was introduced to the amino group of cRGDcys-DC in 0.1 M sodium tetraborate (pH 8.5) over 6 h at room temperature. After incubation, cRGD-cys-DC-TAMRA was purified by the HP1100 HPLC system and reverse-phase PEGASIL ODS column. Cos-1 cells and HUVECs were used as integrin V3-highexpressing and V3-low-expressing cell lines respectively. Both types of cultured cells were seeded onto 96-well plates at 8:0 Â 10 3 cells/well at a final volume of 100 mL, and incubated with 25 mM cRGD-cys-DC-TAMRA under 5% CO 2 for 24 h at 37 C. Internalization of cRGD-cys-DC-TAMRA into the cytoplasm of Cos-1 cells and HUVECs was observed under a fluorescence microscope (IX71; Olympus, Tokyo) by detection of rhodamine (excitation/ emission = 540/570 nm).
Mitochondrial membrane potential assay. The effects of cRGD-cys-DC on the cytoplasmic mitochondria in Cos-1 cells and HUVECs were determined by measuring changes in the mitochondrial membrane potential. Cos-1 cells and HUVECs were seeded in 96-well plates at 5:0 Â 10 4 cells/well at a final volume of 100 mL, and were incubated with and without 50 mM cRGD-cys-DC under 5% CO 2 for 24 h at 37 C. As an indicator of mitochondrial membrane potential, 10 mL of JC-1 staining solution (Cayman Chemical, Ann Arbor, MI) was added to each well. JC-1 spontaneously forms complexes (JC-1 J-aggregates) and shows red fluorescence on healthy mitochondria with high mitochondrial membrane potential, but it remains in monomeric form (as JC-1 monomers) and shows green fluorescence on damaged mitochondria with loss of mitochondrial membrane potential. After Cell membrane leakage assay and apoptosis assay. Cos-1 cells and HUVECs were seeded onto 96-well plates at 8:0 Â 10 3 cells/well in a final volume of 100 mL and incubated with various concentrations of cRGD-cys-DC (12.5, 25, and 50 mM) under 5% CO 2 for 24 h at 37 C. Subsequent assays were performed after peptide treatment.
In the cell membrane leakage assay, cell membrane damage was quantified by measuring the amounts of lactic dehydrogenase (LDH) released from the cytoplasm using a Cytotoxicity Detection Kit (Roche, Basel, Switzerland) following the manufacturer's protocol. Basal LDH release was determined by examination of untreated cells and maximum LDH release was determined from cells treated with 2% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in the medium over 30 min. After treatment of the cells with peptides or Triton X-100, a tetrazolium salt reaction mixture (100 mL/well) was added to each supernatant and this was incubated for 30 min at room temperature. The spectrophotometric absorbance of the colored formazan product, which indicates the amount of LDH released from the cytoplasm, was determined by automated plate reader at a wavelength of 490 nm.
In the apoptosis assay, apoptosis induction was determined by measuring apoptosis indicator caspase 3/7 activity by Caspase-Glo 3/7 Assay (Promega, Madison, WI) according to the manufacturer's protocol. A mixture (100 mL/well) containing a luminogenic caspase 3/7 substrate with a caspase cleavage DEVD sequence was added to each well of cells treated with various concentrations of the peptide. After incubation for 30 min at room temperature, caspase 3/7 activity was determined by measuring the luminescence signals produced from the cleaved caspase 3/7 substrate.
Results

Expression of integrin V3
To evaluate the extracellular expression levels of integrin V3, a target molecule for the cRGD motif, we stained various cell lines with a FITC-labeled antiintegrin V3 antibody and quantified the expression of it by flow cytometric analysis. The mean fluorescent intensity (MFI) of FITC in stained and unstained cells was determined, and the relative integrin V3 expression level was evaluated by calculating the MFI ratio (stained/unstained cells) (Fig. 2) . HUVECs showed high expression of integrin V3 (MFI ¼ 18:1), while the four cell lines Cos-1, RERF-LC-AI, HepG2, and NIH-3T3 showed lower expression levels (MFI ¼ 1:3{3:3).
Cytotoxicities of cRGD-cys-D9mer peptides
The cytotoxic activities of three kinds of peptides, D9mer, cys-D9mer, and cRGD-cys-D9mer peptides, were determined against integrin V3-high and low-expressing cells. The D9mer and cys-D9mer peptides showed no cytotoxicity, with 50% inhibitory concentration (IC 50 ) values above 100 mM, toward all cell lines with and without integrin V3 expression. In contrast, all the cRGD-cys-D9mer peptides exhibited integrin V3 expression-dependent cytotoxicity against HUVECs (IC 50 ¼ 24:2{45:8 mM) ( Table 1 ). The four cRGD-containing peptides showed effective inhibitory activities against the proliferation of HUVECs in the following order: DD > DB > DA ; DC.
Internalization of cRGD-cys-DC
The cRGD motif has been reported to act as an integrin V3-specific delivery sequence. To confirm the integrin V3-specific internalization of a D9mer peptide combined with the cRGD motif, we observed the localization of TAMRA-labeled cRGD-cys-DC in integrin V3-high-expressing HUVECs (MFI ¼ 18:1) and V3-low-expressing Cos-1 cells (MFI ¼ 1:7). Cytotoxicity IC 50 ÃÃ (mM) DA >100 >100 >100 >100 >100 DB >100 >100 >100 >100 >100 DC >100 >100 >100 >100 >100 DD >100 >100 >100 >100 >100
cys-DA >100 >100 >100 >100 >100 cys-DB >100 >100 >100 >100 >100 cys-DC >100 >100 >100 >100 >100 cys-DD >100 >100 >100 >100 >100
cRGD-cys-DA 45.6 >100 >100 >100 >100 cRGD-cys-DB 40.6 >100 >100 >100 >100 cRGD-cys-DC 45.8 >100 >100 >100 >100 cRGD-cys-DD 24.2 >100 >100 >100 >100
Ã Integrin V3 levels were calculated by the mean fluorescence intensity ratio (anti-integrin V3 antibody-FITC stained/non-stained cells) in flow cytometric analyses. ÃÃ IC 50 means the concentration of peptide that is required for 50% inhibition of cell viability relative to untreated cells.
( Fig. 3d) , whereas the Cos-1 cells showed much less red fluorescence (Fig. 3c) under fluorescence microscopy. These observations suggest this D9mer peptide combined with the cRGD peptide translocated into the cytoplasm that in an integrin V3-dependent manner.
Effects of cRGD-cys-DC on mitochondrial potential and apoptosis induction
To examine the intracellular effects of cRGD-cysD9mer peptides, mitochondrial membrane status was observed by JC-1 changes from J-aggregates (red fluorescence) to JC-1 monomers (green fluorescence) in Cos-1 cells and HUVECs treated with 50 mM cRGDcys-DC. The integrin V3-low-expressing Cos-1 cells showed low green fluorescence and high accumulation of red fluorescence, indicating healthy mitochondria with high mitochondrial membrane potential (Fig. 4Aa) . On the other hand, a large increase in green fluorescence and a lack of red fluorescence, which indicates damaged mitochondria with loss of mitochondrial membrane potential, were observed in the HUVECs treated with cRGD-cys-DC (Fig. 4Ab) . This indicates, that cRGDcys-DC damaged the mitochondria and decreased the mitochondrial membrane potential in the HUVECs.
Cell membrane leakage and apoptosis assays were also performed in conjunction with a cell viability assay to elucidate the cytotoxic mechanism of cRGD-cys-DC. The cRGD-cys-DC inhibited the growth of HUVECs at lower concentrations than Cos-1 cells with an increase in apoptosis indicator caspase 3/7 activity and without cell membrane damage, as determined by LDH release. This indicates that cRGD-cys-DC killed integrin V3-high-expressing HUVECs by inducing apoptosis, rather than by disrupting the cell membrane.
Discussion
In this study, we identified selective mitochondrial disruption and cytotoxicity using mitochondria-disruptive D9mer peptides and a tumor-homing cRGD peptide. The cRGD-cys-D9mer peptides effectively killed integrin V3-high-expressing HUVECs, whereas the D9mer and cys-D9mer peptides showed no cytotoxicity toward any of the cell lines examined.
Furthermore, as for the D9mer peptide sequences conjugated with the cRGD peptide, the four peptides showed effective inhibitory activities against the proliferation of HUVECs with the following tendency: DD > DB > DA ; DC. In particular, cRGD-cys-DD showed the lowest IC 50 value (highest cytotoxicity) against HUVECs. The DD sequence (RLLLRIGRR-NH 2 ) contains the largest degree of hydrophobicity and a middle degree of positive charges among the D9mer peptides. On the other hand, DB contains the largest positive charges and a middle degree of hydrophobicity. This suggests that the degrees of hydrophobicity and positive charges in the D9mer sequences are associated with the mitochondria disruptive activities.
We found previously that synthesized peptides DC2 (ALYLAIRRRRRRRR-NH 2 ) and DC (ALYLAIRRR-NH 2 ) conjugated with CPP (octa-arginine: RRRRRRRR-NH 2 ) exhibited clear cytotoxic effects by internalization into the cytoplasm and disruption of the mitochondria. 14) Hence in the present study we used cRGD-cys-DC as a typical peptide complex from among the four cRGDcys-D9mer peptides for comparison with DC2, although cRGD-cys-DC showed the lowest cytotoxicity against HUVECs. Similarly to the case for DC2-TAMRA, cRGD-cys-DC-TAMRA also penetrated the cell membrane and became localized to the cytoplasm of the HUVECs. These findings suggest that cRGD-cys-DC can show effects similar to DC2, viz., mitochondria disruption, in HUVECs. To confirm this, we observed the mitochondrial membrane potential and carried out three assays, for cell viability, cell membrane leakage, and apoptosis induction, in cells treated with cRGD-cys-DC. The cRGD-cys-DC induced, a loss of mitochondrial membrane potential (a change in the JC-1 fluorescence color from red to green), and decreased cell viability with an increase in caspase 3/7 activity in an integrin V3 expression-specific manner. In contrast, the amount of LDH released from the cytoplasm was not affected. Our previous study revealed that cationic D9mer peptides, including DC, disrupt the tumor cell membrane and increase LDH derived from tumor cells, because large amounts of negatively charged phosphatidylserine are expressed on the target tumor membrane surface. 12) However, in the present study, cRGD-cys-DC killed HUVECs with an increase in caspase 3/7 activity without any increase in LDH release. This indicates that cRGD-cys-DC exerts its cytotoxicity by inducing apoptosis without damaging the outer cell membrane, and that uptake of the peptide into HUVECs via the cRGD motif takes place in preference to outer-cell membrane disruption by the DC sequence.
In this study, we succeeded in controlling the cytotoxicity of mitochondria-disruptive peptides by conjugating them with the cRGD motif. Our results suggest that cRGD-cys-D9mer peptides are promising as anti-angiogenesis drugs against integrin V3-highexpressing tumor vasculature cells. In addition, this study illustrates that D9mer peptides have broad utility for mitochondria-targeting strategies focusing on other cell types using other DDSs. It might be worthwhile to test novel combinations of D9mer peptides and other DDSs in the future.
